Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 16.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 155,388 shares of the company's stock after selling 31,583 shares during the period. Motley Fool Wealth Management LLC's holdings in Moderna were worth $6,190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB grew its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna during the 4th quarter valued at $37,000. Venturi Wealth Management LLC raised its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna in the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MRNA. Bank of America cut their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Morgan Stanley cut their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a report on Wednesday, January 15th. UBS Group reduced their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Finally, Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of "Hold" and an average target price of $59.00.

Remove Ads

Moderna Price Performance

NASDAQ:MRNA traded down $1.00 during mid-day trading on Friday, reaching $31.12. The stock had a trading volume of 5,681,801 shares, compared to its average volume of 6,806,216. The stock's 50 day simple moving average is $34.78 and its two-hundred day simple moving average is $44.93. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a market capitalization of $12.03 billion, a price-to-earnings ratio of -3.35 and a beta of 1.86.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.